You are here
Half of statins patients don't achieve 'healthy' cholesterol levels: study
MILLIONS of patients around the world taking statins to lower the risk of heart disease fail to achieve the recommended levels of cholesterol reduction after two years of treatment, new research said on Monday.
Statins - a class of medicines designed to reduce cholesterol linked to heart disease and strokes - are among the most commonly prescribed drugs in the United States and Britain.
The cholesterol-lowering industry is worth billions of dollars, but guidelines over who should take statins are often unclear.
A team of researchers in Britain reviewed public health records of 165,000 patients taking the medicine and found that fewer than one in two reached the recommended "healthy" 40 per cent cholesterol reduction within two years.
"Statins do work and are effective, but some trials have highlighted there have been variations in responses among some patients," said Ralph Kwame Akyea, research associate at the University of Nottingham's Faculty of Medicine and Health Sciences. "But we've shown there are some people not reaching this (safe cholesterol level) and the reducing of their risk is lower," he told AFP.
Mr Akyea's study, published in the journal Heart, found that people on average started taking statins aged 62. It found nearly 23,000 cases of cardiovascular disease within six years of statin treatment among patients.
In total, 51 per cent of patients had an insufficient drop in cholesterol even while taking the drugs.
Mr Akyea stressed that the study - the largest of its kind to date - could not establish why some patients responded positively to statins while others did not.
"Probably some people would have stopped taking their medication, maybe they had side effects," he said. "There might also be a role played by genetic variation. Not everyone responds to the medication, and there are currently studies looking at the genetics of drug response."
Recent changes to prescription guidelines are set to see statins given to more than 55 million people in the US and 12 million people in Britain in the next few years.
Mr Akyea and his team suggested that better guidance and monitoring were needed to ensure that those given statins were taking the correct doses for the prescribed amount of time.
Writing in a linked editorial, Marcio Bittencourt, from Sao Paulo's University Hospital, said that the study's results were "clearly alarming". He stressed, however, that statins had been shown to significantly reduce the likelihood of heart attacks and strokes in a large percentage of at-risk patients.
"Patients and society should be educated on the scientific evidence documenting the benefits of lipid lowering therapy," said Mr Bittencourt. "Anti-statin propaganda based on pseudoscience should be strongly disavowed." AFP